Immunotherapy Trials for Nasopharyngeal Cancers
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Nabil Saba
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Nabil Saba
Disclaimer: This video was recorded prior to the FDA approval on October 27, 2023, of toripalimab-tpzi with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent, locally advanced NPC. FDA also approved toripalimab-tpzi as a single agent for adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.
Login to view comments.
Click here to Login
